Calculus Investment Director Liz Klein discusses investment strategies with Wealth Club

“That’s what wakes me up in the morning [… seeking] a positive return on investment, and we get to make sure that people have longer, healthier, happier lifespans.” – Wealth Club talk investing in life sciences, technology and media content with Elizabeth Klein of Calculus Capital.

In this interview:
‣ Backing Laverock Therapeutics – novel gene silencing technology from a repeat entrepreneur David Venables, coinvesting with Lilly Ventures
‣ Investing in Tagomics – detection of origins of cancer, spun out from University of Birmingham, coinvesting with Illumina Ventures and Agilent Technologies
‣ How do past investments in Horizon Discovery and Synpromics help Calculus win deals?
‣ Maturing holdings Oxford BioTherapeutics and Tozaro
‣ Exits, including ActiveOps
‣ Risks, risk management, and current opportunities in venture capital

IMPORTANT The opinions expressed in this video are the interviewee’s own and do not necessarily reflect the view of Wealth Club Limited. This interview, like our service, is not advice. The investments described are high risk and illiquid.